Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis.
about
Treatment of inflammatory myopathy: emerging therapies and therapeutic targetsRespiratory symptoms and disease characteristics as predictors of pulmonary function abnormalities in patients with rheumatoid arthritis: an observational cohort study.Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemmaAnti-cyclic citrullinated Peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis.Methotrexate-induced pneumonitis in Crohn's disease. Case report and review of the literatureDiagnosis and treatment of connective tissue disease-associated interstitial lung disease.Methotrexate-induced pulmonary toxicity.Inflammatory arthritis: an overview for primary care physicians.Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury.Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis.Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists.The safety of non-biological treatments in Ulcerative Colitis.Safety profile of methotrexate in inflammatory bowel disease.Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review.Low-dose methotrexate-induced acute interstitial pneumonitis: Report of two cases from South India and review of literature.Acute methotrexate toxicity presenting as multiorgan failure and acute pneumonitis: A rare case reportMethotrexate-induced Hypersensitivity Pneumonitis appearing after 30 years of use: a case report.Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study.Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis.Methotrexate-induced pneumonia: A dermatologist wake up call.
P2860
Q26796546-3D4343F3-E1F3-42B1-B0A3-B461A27FCDC4Q34027546-B973B8BC-5256-4078-AA10-0D9D18274265Q35029858-816EBD3C-2B36-415F-A9F2-772DA5889474Q35151573-7F56F53F-34A0-456A-B78D-1907CA9D95E1Q36293824-CEB88AA7-9FCD-487C-81C4-89C2302B9DBEQ36664408-EAF82131-936D-4DB6-9CD8-AC818D03ECF5Q37270945-85CB68C8-F5D4-44C7-B212-7FE25F0126A9Q37427257-65B85F02-CEF6-437D-B4CC-53DA62951B59Q37701147-498E1F91-0934-49A2-924C-67FF7A44B7E5Q37853577-5CAB0478-7241-42EA-98F4-6288BB1B40D7Q38125245-279A22DB-1579-4280-AF3C-EC70754F5FD7Q38411930-BE65B020-3E19-48B0-8C68-DCD59D6C91F5Q38728164-984AFD2F-B188-4BDE-BC11-0B1F1D27739DQ38909929-0253E47C-955D-484E-9E6F-92F88132F3E0Q38979114-D95C738D-162A-476D-A5A2-12E59C751ADBQ39203960-22C5C242-F887-45C6-BDFE-5EFBFF80B13AQ39378854-FEF7FC50-E908-490D-A5D7-47C75C23CFEBQ40050921-367D18CE-D290-44A1-816D-B6472873BA7FQ41840744-2FB73AED-A11C-45B4-85F5-E445CB9DC0CAQ45036337-37955EB1-D8DA-4993-A860-6D0BFC2A818CQ48218136-49AF037D-3A6C-4619-966E-7F352A22079A
P2860
Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis.
@ast
Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis.
@en
type
label
Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis.
@ast
Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis.
@en
prefLabel
Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis.
@ast
Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis.
@en
P356
P1433
P1476
Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis.
@en
P2093
P304
P356
10.1093/RHEUMATOLOGY/KEG466
P577
2003-08-15T00:00:00Z